Zhuang Renxiang said that he had previously mentioned to Shanghai Fosun Pharma that he wanted to switch to the BNT next-generation bivalent vaccine, "but the other party did not agree." At that time, there was no such flexibility. Now the policy change is of course an expression of gratitude.

(file photo)

[Central News Agency] In response to the BNT next-generation vaccine storm, Shanghai Fosun Pharma stated that all future orders can be replaced by BNT next-generation bivalent COVID-19 vaccine.

Zhuang Renxiang, spokesman of the command center, said tonight that he had requested a replacement but was rejected, and that the BNT vaccine will still be considered for procurement in the future.

Hon Hai founder Terry Gou recently called on Taiwan to import the BNT next-generation bivalent COVID-19 (coronavirus disease 2019) vaccine. Wang Bisheng, commander of the Central Epidemic Command Center, said yesterday that he had tried to replace the undelivered BNT monovalent COVID-19 vaccine Generations of bivalent vaccines, but due to the lack of relevant content in the contract, it is impossible to compare them with Moderna.

Please read on...

Shanghai Fosun Pharma issued a press release today stating that, as BNT’s exclusive partner for COVID-19 vaccines in the Greater China region (including Taiwan), it will always supply vaccines to Taiwan in accordance with the agreement and normal business rules to help strengthen epidemic prevention and control, assist People in Taiwan will return to normal life as soon as possible.

Shanghai Fosun Pharma stated that under the framework of the procurement contract signed with the Taiwan Centers for Disease Control and Prevention, all future orders can be replaced with BNT next-generation bivalent vaccines; in addition, it has submitted to the relevant Taiwan authorities on December 4 the vaccine for children aged 5 to 11. Emergency Use Authorization (EUA) for next-generation vaccines for populations.

In this regard, Zhuang Renxiang told the Central News Agency reporter in the evening that he had previously mentioned to Shanghai Fosun Pharma that he wanted to change, "but the other party did not agree." At that time, there was no such flexibility. Now the policy change is of course an expression of gratitude.

Zhuang Renxiang pointed out that at present, there are about 3.13 million doses of Moderna's next-generation bivalent vaccine remaining in China, and there will still be 15 million doses of vaccine contracts with Moderna next year, which is sufficient, but the BNT vaccine will still be included in the procurement considerations. It depends on the situation of the epidemic.

Related news please see:

Please click here for the "Wuhan Pneumonia Zone", for more information, you can grasp it first-hand.